Nordic Nanovector to explore strategic options
Oslo, Norway, 18 August 2022 Nordic Nanovector ASA (OSE: NANOV) (“Nordic Nanovector” or the “Company”) today announces that its Board of Directors (the “Board”) has appointed Carnegie Investment Bank (“Carnegie”) to explore strategic options available to the Company. The Board has initiated this review aiming to optimise shareholder value following its recent decision to discontinue the PARADIGME study for Nordic Nanovector’s lead asset Betalutin® and implement a restructuring of the Company. Chairman, Jan H. Egberts commented: “The decision to discontinue the PARADIGME study was